Bain Capital has increased its offer price for Tokyo-listed aged care provider Nichii Gakkan – after a Hong Kong hedge fund criticized the board for not doing enough to protect the interests of minority shareholders – valuing the business at JPY122 billion ($1.15 billion).
The private equity firm won board support in May for a tender offer of JPY1,500 per share. It now stands at JPY1,650 per share, according to a filing, which represents a 52.6% premium to the May 7 closing...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.